Connect your AI

Evommune EVMN Change in fair value of the conversion option of the convertible senior notes

Change in fair value of the conversion option of the convertible senior notes at other companies

AMC Entertainment HoldingsAMC

$59.5M+31.9%

Eastman Kodak CompanyKODK

-$12M—

Medline, Inc. MDLN

$10.25M—

BridgeBio PharmaBBIO

$2.16M-45.4%

ASP Isotopes, Inc.ASPI

-$568K+40.6%

Red Cat Holdings, Inc.RCAT

$867K-91.9%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's change in fair value of the conversion option of the convertible senior notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's change in fair value of the conversion option of the convertible senior notes?: Evommune (EVMN) reported change in fair value of the conversion option of the convertible senior notes of -$78.43K in Q1 2026.